Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Public ClinicalTrials.gov record NCT02570542. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Study identification
- NCT ID
- NCT02570542
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Enrollment
- 59 participants
Conditions and interventions
Conditions
Interventions
- Autologous Stem Cell Transplantation Procedure
- Plerixafor Drug
- carmustine, etoposide, cytarabine, melphalan Drug
- leukapheresis Procedure
Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2015
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2026
- Last update posted
- Nov 25, 2025
2015 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 6
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Nebraska Medical Center | Omaha | Nebraska | 68198-7680 | — |
| Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up Only) | Basking Ridge | New Jersey | — | — |
| Memorial Sloan Kettering Monmouth (Consent and Follow up Only) | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering Bergen (Consent and Follow Up Only) | Montvale | New Jersey | 07645 | — |
| Memorial Sloan Kettering Commack (Consent and Follow-up Only) | Commack | New York | 11725 | — |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | — |
| Northwell Health (Data collection only) | Manhasset | New York | 11030 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Columbia University | New York | New York | — | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Memorial Sloan Kettering Nassau (Consent and Follow up Only) | Uniondale | New York | 11553 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Transplant Institute | San Antonio | Texas | 78229 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02570542, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02570542 live on ClinicalTrials.gov.